공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

과민성 대장 증후군 : 파이프라인 리뷰

Irritable Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 232842
페이지 정보 영문 204 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


과민성 대장 증후군 : 파이프라인 리뷰 Irritable Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 204 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

과민성 대장 증후군(IBS)은 만성적 혹은 재발성 면역반응을 수반하는 증상과 소화관의 염증을 나타내는 용어입니다. 증후는 복부 경련과 통증, 피 섞인 설사, 체중 감소, 식욕 부진, 열 등입니다. 소인으로서 연령, 가족력, 흡연, 진통제 등을 들 수 있습니다. 치료에는 부신피질스테로이드, 면역제제, 항생물질, 진정제 등을 이용합니다.

세계 각국의 과민성 대장 증후군(IBS) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

과민성 대장 증후군 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관에서 개발된 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

과민성 대장 증후군 치료제 개발 참여 기업

  • 4D Pharma PLC
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Alfa Wassermann SpA
  • Allergan Plc
  • Ardelyx Inc
  • Astellas Pharma Inc.
  • CJ HealthCare Corp
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co., Ltd.
  • Eisai Inc.
  • Enterome Bioscience SA
  • GlaxoSmithKline Plc
  • Innovative Med Concepts LLC
  • Ironwood Pharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Lexicon Pharmaceuticals Inc
  • Napo Pharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • SK Biopharmaceuticals Co Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Synergy Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Vitality Biopharma Inc

약제 개요

과민성 대장 증후군 : 휴지 상태의 프로젝트

과민성 대장 증후군 : 개발이 중지된 제품

과민성 대장 증후군 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Irritable Bowel Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, 2021
  • Irritable Bowel Syndrome - Pipeline by AbbVie Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by AsiaBiome, 2021
  • Irritable Bowel Syndrome - Pipeline by Assembly Biosciences Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Axim Biotechnologies Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Bausch Health Companies Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Biomica, 2021
  • Irritable Bowel Syndrome - Pipeline by Blue Therapeutics Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Boston Pharmaceuticals Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by CB2 Therapeutics Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by CinRx Pharma LLC, 2021
  • Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, 2021
  • Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by Emyria Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by Exeliom Biosciences SAS, 2021
  • Irritable Bowel Syndrome - Pipeline by GEXVal Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by HK inno.N Corp, 2021
  • Irritable Bowel Syndrome - Pipeline by IGY Immune Technologies & Life Sciences Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, 2021
  • Irritable Bowel Syndrome - Pipeline by Immunic Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by ISOThrive Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by Metacrine Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by MGC Pharmaceuticals Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Neurocrine Biosciences Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Nexpharm Korea Co Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by Novome Biotechnologies Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Orphomed Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Oxford Cannabinoid Technologies Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by PeptiDream Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by Renexxion LLC, 2021
  • Irritable Bowel Syndrome - Pipeline by Seed Health Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Serenity Bioworks Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Serentrix LLC, 2021
  • Irritable Bowel Syndrome - Pipeline by Servatus Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by TenNor Therapeutics Ltd, 2021
  • Irritable Bowel Syndrome - Pipeline by Velicept Therapeutics Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Virios Therapeutics, Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, 2021
  • Irritable Bowel Syndrome - Pipeline by Zhiyi Pharmaceuticals Inc, 2021
  • Irritable Bowel Syndrome - Dormant Projects, 2021
  • Irritable Bowel Syndrome - Dormant Projects, 2021 (Contd..1)
  • Irritable Bowel Syndrome - Dormant Projects, 2021 (Contd..2)
  • Irritable Bowel Syndrome - Dormant Projects, 2021 (Contd..3)
  • Irritable Bowel Syndrome - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Irritable Bowel Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Drugs In Development, 2021, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 11, 1, 15, 8 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Irritable Bowel Syndrome - Overview
  • Irritable Bowel Syndrome - Therapeutics Development
  • Irritable Bowel Syndrome - Therapeutics Assessment
  • Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
  • Irritable Bowel Syndrome - Drug Profiles
  • Irritable Bowel Syndrome - Dormant Projects
  • Irritable Bowel Syndrome - Discontinued Products
  • Irritable Bowel Syndrome - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q